Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study

OBJECTIVES: The benefit of sequential therapy after immune checkpoint inhibitor (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest in the impact of cetuximab (Cmab)-containing salvage chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakasaki, Takahiro, Manako, Tomomi, Yasumatsu, Ryuji, Hara, Hirotaka, Toh, Satoshi, Masuda, Muneyuki, Yamauchi, Moriyasu, Kuratomi, Yuichiro, Nishimura, Emi, Takeuchi, Toranoshin, Matsuo, Mioko, Jiromaru, Rina, Hashimoto, Kazuki, Komune, Noritaka, Nakagawa, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333293/
https://www.ncbi.nlm.nih.gov/pubmed/35901098
http://dx.doi.org/10.1371/journal.pone.0271907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333293/
https://www.ncbi.nlm.nih.gov/pubmed/35901098
http://dx.doi.org/10.1371/journal.pone.0271907

Ejemplares similares